Atopic Dermatitis - Pipeline Review, H1 2017


#1027645

374pages

Global Markets Direct

$ 2000

In Stock

Atopic Dermatitis - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis Pipeline Review, H1 2017, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.

Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 40, 21, 1, 44, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 2 and 2 molecules, respectively.

Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Atopic Dermatitis - Overview 12
Atopic Dermatitis - Therapeutics Development 13
Pipeline Overview 13
Pipeline by Companies 14
Pipeline by Universities/Institutes 20
Products under Development by Companies 21
Products under Development by Universities/Institutes 28
Atopic Dermatitis - Therapeutics Assessment 29
Assessment by Target 29
Assessment by Mechanism of Action 33
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Atopic Dermatitis - Companies Involved in Therapeutics Development 41
AbbVie Inc 41
Accolade Pharmaceuticals LLC 41
Albireo Pharma Inc 42
Almirall SA 42
Amgen Inc 43
Amorepacific Corp 43
AnaptysBio Inc 44
AnGes MG Inc 44
Antibiotx ApS 45
Avexxin AS 45
Blueberry Therapeutics Ltd 46
Brickell Biotech Inc 46
Celgene Corp 47
Cell Medica Ltd 47
Cellceutix Corp 48
ChemoCentryx Inc 48
ChironWells GmbH 49
Chugai Pharmaceutical Co Ltd 49
Clevexel Pharma SA 50
Curapel Ltd 50
Cutanea Life Sciences Inc 51
Dermala Inc 51
Dr. August Wolff GmbH & Co KG Arzneimittle 52
Eli Lilly and Company 52
Exicure Inc 53
F. Hoffmann-La Roche Ltd 53
Foamix Pharmaceuticals Ltd 54
Fountain Biopharma Inc 54
Galapagos NV 55
Galectin Therapeutics Inc 55
GlaxoSmithKline Plc 56
Glenmark Pharmaceuticals Ltd 56
Grupo Ferrer Internacional SA 57
GTx Inc 57
Han Wha Pharma Co Ltd 58
HanAll Biopharma Co Ltd 58
Heptares Therapeutics Ltd 59
Herantis Pharma Plc 59
iCo Therapeutics Inc. 60
Immune Pharmaceuticals Inc 60
Incyte Corp 61
Inflamalps SA 61
Japan Tobacco Inc 62
Kang Stem Biotech Co Ltd 62
KPI Therapeutics Inc 63
LEO Pharma A/S 63
Madam Therapeutics BV 64
MedImmune LLC 64
NeoPharm Co Ltd 65
Novan Inc 65
Novartis AG 66
Orbis Biosciences Inc 66
Otsuka Holdings Co Ltd 67
Oxagen Ltd 67
Pfizer Inc 68
Pharis Biotec GmbH 68
Pharmedartis GmbH 69
Provectus Biopharmaceuticals Inc 69
Qurient Co Ltd 70
Realm Therapeutics Plc 70
Regeneron Pharmaceuticals Inc 71
Roivant Sciences Ltd 71
Signum Biosciences Inc 72
Signum Dermalogix Inc 72
Spherium Biomed SL 73
sterna biologicals Gmbh & Co KG 73
Sun Pharma Advanced Research Company Ltd 74
SWITCH Biotech LLC 74
Thesan Pharmaceuticals Inc 75
Torrent Pharmaceuticals Ltd 75
Trevi Therapeutics Inc 76
Valeant Pharmaceuticals International Inc 76
Vicore Pharma AB 77
Vitae Pharmaceuticals Inc 77
VivaCell Biotechnology Espana SL 78
Xencor Inc 78
Zhejiang I-Biological Technology Co Ltd 79
Atopic Dermatitis - Drug Profiles 80
A-3914 - Drug Profile 80
A-5425 - Drug Profile 81
AKP-11 - Drug Profile 82
Allergen for House Dust Mite Induced Atopic Dermatitis - Drug Profile 84
ALX-101 - Drug Profile 85
AMG-0101 - Drug Profile 86
Anatabine - Drug Profile 88
ANB-020 - Drug Profile 91
Antisense Oligonucleotide to Antagonize IL-4RA for Atopic Dermatitis - Drug Profile 93
apremilast - Drug Profile 94
Aptamers to Inhibit Galectin-3 for Atopic Dermatitis - Drug Profile 106
ARN-077 - Drug Profile 107
AVX-001 - Drug Profile 108
AZT-01 - Drug Profile 110
B-244 - Drug Profile 111
baricitinib - Drug Profile 113
BB-2702 - Drug Profile 123
BBI-2000 - Drug Profile 124
BBI-5000 - Drug Profile 125
bertilimumab - Drug Profile 126
betamethasone valerate - Drug Profile 130
Biologic for Atopic Dermatitis - Drug Profile 131
Biologic for Atopic Dermatitis and Eczema - Drug Profile 132
brilacidin tetrahydrochloride - Drug Profile 133
BTX-1204 - Drug Profile 144
C-21 - Drug Profile 145
CBP-174 - Drug Profile 148
CBP-201 - Drug Profile 149
CCX-6239 - Drug Profile 150
CDE-001 - Drug Profile 151
Cis-Urocanic Acid - Drug Profile 152
cobamamide - Drug Profile 154
CT-101 - Drug Profile 156
CT-103 - Drug Profile 157
CVXL-0074 - Drug Profile 158
cyclosporin - Drug Profile 159
cyclosporine - Drug Profile 160
dalazatide - Drug Profile 161
DMT-210 - Drug Profile 166
Drug for Atopic Dermatitis - Drug Profile 168
Drug for Atopic Dermatitis - Drug Profile 169
dupilumab - Drug Profile 170
FB-825 - Drug Profile 179
fevipiprant - Drug Profile 180
FIB-116 - Drug Profile 182
FM-1202 - Drug Profile 183
Furestem-AD - Drug Profile 184
GBR-830 - Drug Profile 185
GLPG-2534 - Drug Profile 186
GRMD-02 - Drug Profile 187
GSK-3772847A - Drug Profile 200
Gtx-186 - Drug Profile 201
Histimex - Drug Profile 202
house dust mite (Dermatophagoides farinae) allergen extract - Drug Profile 203
HS-378 - Drug Profile 204
IDP-124 - Drug Profile 205
INV-25 - Drug Profile 206
INV-88 - Drug Profile 207
JTE-052 - Drug Profile 208
K-1032 - Drug Profile 209
KPI-150 - Drug Profile 210
lebrikizumab - Drug Profile 211
LEKTI-6 - Drug Profile 215
LP-0058 - Drug Profile 216
LP-0108 - Drug Profile 217
LP-0145 - Drug Profile 218
LP-0155 - Drug Profile 219
MEDI-9314 - Drug Profile 220
mepolizumab - Drug Profile 221
MLR-1130 - Drug Profile 227
mometasone furoate - Drug Profile 228
Monoclonal Antibody to Antagonize PAR-2 for Atopic Dermatitis and Inflammation - Drug Profile 229
Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis - Drug Profile 230
MOR-106 - Drug Profile 231
MSB-01 - Drug Profile 233
nalbuphine hydrochloride ER - Drug Profile 234
nemolizumab - Drug Profile 238
niclosamide - Drug Profile 240
NPB-311 - Drug Profile 242
NPH-12 - Drug Profile 243
OC-2417 - Drug Profile 244
octenidine hydrochloride - Drug Profile 245
OLX-103 - Drug Profile 246
omiganan pentahydrochloride - Drug Profile 247
OPA-15406 - Drug Profile 250
P-10 - Drug Profile 252
P-148 - Drug Profile 253
PAC-14028 - Drug Profile 254
Peptide to Antagonize CX3CR1 for Atopic Dermatitis - Drug Profile 256
Peptides to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile 257
PF-04965842 - Drug Profile 258
PF-06817024 - Drug Profile 259
PH-10 - Drug Profile 260
PL-601 - Drug Profile 263
PMA-101R - Drug Profile 264
PMA-201 - Drug Profile 265
PMA-411R - Drug Profile 266
PR-022 - Drug Profile 267
prednisone - Drug Profile 269
PZ-235 - Drug Profile 270
ruxolitinib phosphate - Drug Profile 271
RVT-201 - Drug Profile 286
RVT-501 - Drug Profile 287
SB-011 - Drug Profile 289
SB-414 - Drug Profile 290
secukinumab - Drug Profile 291
SIG-1322 - Drug Profile 305
SIG-1451 - Drug Profile 306
Small Molecule for Atopic Dermatitis - Drug Profile 307
Small Molecule to Modulate S1PR1 for Atopic Dermatitis - Drug Profile 308
Small Molecules for Atopic Dermatitis - Drug Profile 309
Small Molecules for Atopic Dermatitis - Drug Profile 310
Small Molecules to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile 311
SNA-120 - Drug Profile 312
SNA-125 - Drug Profile 315
SUN-0597 - Drug Profile 316
SWT-01113 - Drug Profile 318
SWT-05141 - Drug Profile 319
Synthetic Peptides to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders - Drug Profile 320
tacrolimus - Drug Profile 321
tezepelumab - Drug Profile 322
tralokinumab - Drug Profile 324
upadacitinib tartrate - Drug Profile 327
VTP-38543 - Drug Profile 330
WBI-1001 - Drug Profile 332
WOL-071007 - Drug Profile 334
XmAb-7195 - Drug Profile 335
YJC-10592 - Drug Profile 337
Zafi-1 - Drug Profile 338
zafirlukast - Drug Profile 339
zileuton - Drug Profile 340
ZPL-389 - Drug Profile 341
ZPL-521 - Drug Profile 343
Atopic Dermatitis - Dormant Projects 344
Atopic Dermatitis - Discontinued Products 350
Atopic Dermatitis - Product Development Milestones 351
Featured News & Press Releases 351
Appendix 364
Methodology 364
Coverage 364
Secondary Research 364
Primary Research 364
Expert Panel Validation 364
Contact Us 364
Disclaimer 365

List of Tables
Number of Products under Development for Atopic Dermatitis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Atopic Dermatitis - Pipeline by AbbVie Inc, H1 2017
Atopic Dermatitis - Pipeline by Accolade Pharmaceuticals LLC, H1 2017
Atopic Dermatitis - Pipeline by Albireo Pharma Inc, H1 2017
Atopic Dermatitis - Pipeline by Almirall SA, H1 2017
Atopic Dermatitis - Pipeline by Amgen Inc, H1 2017
Atopic Dermatitis - Pipeline by Amorepacific Corp, H1 2017
Atopic Dermatitis - Pipeline by AnaptysBio Inc, H1 2017
Atopic Dermatitis - Pipeline by AnGes MG Inc, H1 2017
Atopic Dermatitis - Pipeline by Antibiotx ApS, H1 2017
Atopic Dermatitis - Pipeline by Avexxin AS, H1 2017
Atopic Dermatitis - Pipeline by Blueberry Therapeutics Ltd, H1 2017
Atopic Dermatitis - Pipeline by Brickell Biotech Inc, H1 2017
Atopic Dermatitis - Pipeline by Celgene Corp, H1 2017
Atopic Dermatitis - Pipeline by Cell Medica Ltd, H1 2017
Atopic Dermatitis - Pipeline by Cellceutix Corp, H1 2017
Atopic Dermatitis - Pipeline by ChemoCentryx Inc, H1 2017
Atopic Dermatitis - Pipeline by ChironWells GmbH, H1 2017
Atopic Dermatitis - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017
Atopic Dermatitis - Pipeline by Clevexel Pharma SA, H1 2017
Atopic Dermatitis - Pipeline by Curapel Ltd, H1 2017
Atopic Dermatitis - Pipeline by Cutanea Life Sciences Inc, H1 2017
Atopic Dermatitis - Pipeline by Dermala Inc, H1 2017
Atopic Dermatitis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, H1 2017
Atopic Dermatitis - Pipeline by Eli Lilly and Company, H1 2017
Atopic Dermatitis - Pipeline by Exicure Inc, H1 2017
Atopic Dermatitis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Atopic Dermatitis - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017
Atopic Dermatitis - Pipeline by Fountain Biopharma Inc, H1 2017
Atopic Dermatitis - Pipeline by Galapagos NV, H1 2017
Atopic Dermatitis - Pipeline by Galectin Therapeutics Inc, H1 2017
Atopic Dermatitis - Pipeline by GlaxoSmithKline Plc, H1 2017
Atopic Dermatitis - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017
Atopic Dermatitis - Pipeline by Grupo Ferrer Internacional SA, H1 2017
Atopic Dermatitis - Pipeline by GTx Inc, H1 2017
Atopic Dermatitis - Pipeline by Han Wha Pharma Co Ltd, H1 2017
Atopic Dermatitis - Pipeline by HanAll Biopharma Co Ltd, H1 2017
Atopic Dermatitis - Pipeline by Heptares Therapeutics Ltd, H1 2017
Atopic Dermatitis - Pipeline by Herantis Pharma Plc, H1 2017
Atopic Dermatitis - Pipeline by iCo Therapeutics Inc., H1 2017
Atopic Dermatitis - Pipeline by Immune Pharmaceuticals Inc, H1 2017
Atopic Dermatitis - Pipeline by Incyte Corp, H1 2017
Atopic Dermatitis - Pipeline by Inflamalps SA, H1 2017
Atopic Dermatitis - Pipeline by Japan Tobacco Inc, H1 2017
Atopic Dermatitis - Pipeline by Kang Stem Biotech Co Ltd, H1 2017
Atopic Dermatitis - Pipeline by KPI Therapeutics Inc, H1 2017
Atopic Dermatitis - Pipeline by LEO Pharma A/S, H1 2017
Atopic Dermatitis - Pipeline by Madam Therapeutics BV, H1 2017
Atopic Dermatitis - Pipeline by MedImmune LLC, H1 2017
Atopic Dermatitis - Pipeline by NeoPharm Co Ltd, H1 2017
Atopic Dermatitis - Pipeline by Novan Inc, H1 2017
Atopic Dermatitis - Pipeline by Novartis AG, H1 2017
Atopic Dermatitis - Pipeline by Orbis Biosciences Inc, H1 2017
Atopic Dermatitis - Pipeline by Otsuka Holdings Co Ltd, H1 2017
Atopic Dermatitis - Pipeline by Oxagen Ltd, H1 2017
Atopic Dermatitis - Pipeline by Pfizer Inc, H1 2017
Atopic Dermatitis - Pipeline by Pharis Biotec GmbH, H1 2017
Atopic Dermatitis - Pipeline by Pharmedartis GmbH, H1 2017
Atopic Dermatitis - Pipeline by Provectus Biopharmaceuticals Inc, H1 2017
Atopic Dermatitis - Pipeline by Qurient Co Ltd, H1 2017
Atopic Dermatitis - Pipeline by Realm Therapeutics Plc, H1 2017
Atopic Dermatitis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
Atopic Dermatitis - Pipeline by Roivant Sciences Ltd, H1 2017
Atopic Dermatitis - Pipeline by Signum Biosciences Inc, H1 2017
Atopic Dermatitis - Pipeline by Signum Dermalogix Inc, H1 2017
Atopic Dermatitis - Pipeline by Spherium Biomed SL, H1 2017
Atopic Dermatitis - Pipeline by sterna biologicals Gmbh & Co KG, H1 2017
Atopic Dermatitis - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
Atopic Dermatitis - Pipeline by SWITCH Biotech LLC, H1 2017
Atopic Dermatitis - Pipeline by Thesan Pharmaceuticals Inc, H1 2017
Atopic Dermatitis - Pipeline by Torrent Pharmaceuticals Ltd, H1 2017
Atopic Dermatitis - Pipeline by Trevi Therapeutics Inc, H1 2017
Atopic Dermatitis - Pipeline by Valeant Pharmaceuticals International Inc, H1 2017
Atopic Dermatitis - Pipeline by Vicore Pharma AB, H1 2017
Atopic Dermatitis - Pipeline by Vitae Pharmaceuticals Inc, H1 2017
Atopic Dermatitis - Pipeline by VivaCell Biotechnology Espana SL, H1 2017
Atopic Dermatitis - Pipeline by Xencor Inc, H1 2017
Atopic Dermatitis - Pipeline by Zhejiang I-Biological Technology Co Ltd, H1 2017
Atopic Dermatitis - Dormant Projects, H1 2017
Atopic Dermatitis - Dormant Projects, H1 2017 (Contd..1), H1 2017
Atopic Dermatitis - Dormant Projects, H1 2017 (Contd..2), H1 2017
Atopic Dermatitis - Dormant Projects, H1 2017 (Contd..3), H1 2017
Atopic Dermatitis - Dormant Projects, H1 2017 (Contd..4), H1 2017
Atopic Dermatitis - Dormant Projects, H1 2017 (Contd..5), H1 2017
Atopic Dermatitis - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Atopic Dermatitis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017